Key facts
- It has raised $21.2M; the latest was Later Stage VC ($10.0M) in May 2024.
- Notable investors include MassChallenge, Innovation Authority, Howard Morgan, BioGiv Excubator, Calcalist — 12 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 12 names
- ·Watchlist + deal alerts for NeuroKaire
- ·The full record, as it builds
Funding rounds
No funding rounds for NeuroKaire are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About NeuroKaire
Operator of a medical platform intended to transform brain health and eliminate suffering precision medicine in psychiatry and neurology. The company's innovative technology also provides pharmaceutical companies with essential tools for targeted drug discovery and development, enabling clinicians to identify the optimal antidepressant based on the unique response of a patient's brain cells combined with their genetics and medical history.
- Sector
- Healthcare
- HQ
- Kearny, NJ, United States
- Founded
- 2018
- Employees
- 44
- Website
- neurokaire.com/
- Ownership
- Privately Held (backing)
NeuroKaire doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in NeuroKaire shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on NeuroKaire in its N-PORT filings yet. We sweep new filings monthly.